Caliper Ingredients commissioned Colorado State University (CSU) to conduct a clinical study of commercially available CBD-infused food and supplement product pharmacokinetics.
Pharmacokinetics looks at how bioactives diffuse through the body, highlighting the difference between what is consumed and what is absorbed, as well the rate and efficiency of absorption.
„More than 20 million Americans use CBD daily, and trends show that number continuing to rise,” said Christopher Bell, PhD, lead researcher with the CSU team. „But there is so little we understand about CBD, and how everything from product format to individual physiology can affect circulating blood concentrations over time. The industry simply lacks basic scientific research and substantiation. We partnered with Caliper because they share our drive to better understand CBD and its effects on the human body, which was why testing with humans—and publishing the results in a peer-reviewed journal — was essential.”
The research, published in a special edition of Pharmaceuticals titled Cannabidiol: Advances in Therapeutic Applications and Future Perspectives, was approved by an Institutional Review Board (IRB) in compliance with the requirements of 45 CFR 46 for human clinical research.
Study details
Researchers compared the pharmacokinetic profiles of three proprietary soluble CBD formats against two control formats.
Conducted by CSU research scientists, this blinded, randomized, crossover study design included 15 healthy men and women, 21-62 years of age, with each participant consuming 30mg of CBD in five product formats. Three of Caliper’s proprietary dissolvable CBD formulations were tested against two controls: a standardized, oil-based CBD tincture and a CBD isolate, which together represent the two of the more common CBD product formats available to consumers today. Participants provided intravenous blood samples prior to ingestion, and then at regular intervals over the ensuing four hours.